Please check your internet connection and try again.
# Pantoprazole
## Overview
Pantoprazole is a proton pump inhibitor (PPI) that reduces gastric acid production.
## Primary Indications
* Healing of erosive esophagitis associated with gastroesophageal reflux disease (GERD).
* Maintenance of healing of erosive esophagitis.
* Treatment of pathological hypersecretory conditions, including Zollinger-Ellison syndrome.
## Adult Dosing
* **Erosive esophagitis:** 40 mg orally once daily for up to 8 weeks. For maintenance, 40 mg orally once daily.
* **Pathological hypersecretory conditions:** Starting dose is typically 40 mg orally twice daily, may be increased to a maximum of 240 mg daily divided into two doses. Dosing is highly individualized.
## Pediatric Dosing
* **Erosive esophagitis (age 5 to 16 years):** 20 mg or 40 mg orally once daily based on weight (less than 40 kg: 20 mg; 40 kg or more: 40 mg). Duration up to 8 weeks.
* **GERD (age 6 months to 16 years):** 20 mg or 40 mg orally once daily based on weight (less than 40 kg: 20 mg; 40 kg or more: 40 mg).
## Dose Adjustments
No specific dose adjustments are required for patients with hepatic or renal impairment based on standard dosing. However, caution may be advised in severe hepatic impairment.
## Contraindications
Known hypersensitivity to pantoprazole or any of its components.
## Adverse Effects
Common: Diarrhea, headache, nausea, abdominal pain, dizziness, flatulence.
Long-term use (typically over 1 year) may be associated with an increased risk of:
* Fractures (hip, wrist, spine)
* Clostridium difficile infection
* Vitamin B12 deficiency
* Hypomagnesemia
## Key Drug Interactions
* **Drugs requiring gastric acid for absorption:** Pantoprazole can decrease absorption of drugs like ketoconazole, itraconazole, posaconazole, iron salts, and vitamin B12.
* **Methotrexate:** PPIs may increase methotrexate levels, potentially leading to toxicity.
* **CYP2C19 substrates:** Pantoprazole is a moderate inhibitor of CYP2C19; co-administration with substrates like clopidogrel may reduce their efficacy, though clinical significance is debated.
## Monitoring
* Monitor for signs and symptoms of C. difficile infection.
* Consider monitoring magnesium levels in patients on long-term therapy, especially if taking concomitant medications like diuretics.
* Evaluate for potential vitamin B12 deficiency with prolonged use.
## Clinical Pearls
* Administer pantoprazole oral suspension and delayed-release tablets at least 2 hours before or 2 hours after meals for optimal absorption. Pantoprazole IV can be administered without regard to meals.
* For patients unable to swallow whole tablets, the delayed-release tablets can be crushed and mixed with 100 mL of applesauce or apple juice, or 2 tablespoons of applesauce. The mixture should be consumed within 30 minutes.
* Long-term use should be reserved for patients who require ongoing therapy and at the lowest effective dose.
***
**Disclaimer:** This information is intended for clinical use and is not a substitute for professional medical advice. Always consult the most current prescribing information and relevant literature for complete details and to verify dosages and indications, as they may vary based on specific patient factors and local guidelines.
